News | November 14, 2025
Novartis opens radioligand therapy facility in Carlsbad, US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Subscribe To Our Newsletter & Stay Updated
